Recently, bromodomain-containing protein 4 (BRD4), which is overexpressed in AML, was reported to elevate B7H6 expression in AML blasts, and patients with high B7H6 expression showed poor prognosis, further strengthening B7H6 as a therapeutic target [24]. The gene discussed is NCR3LG1; the disease is acute myeloid leukemia.